<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>UNITED
STATES</B></FONT><FONT STYLE="font-size: 10pt"><BR>
</FONT><FONT STYLE="font-size: 18pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
</B></FONT><B><FONT STYLE="font-size: 10pt">WASHINGTON, D.C. 20549</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT STYLE="font-size: 10pt"><BR>
<BR>
</FONT></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
<FONT STYLE="font-size: 18pt"><B>FORM 8-K<BR>
</B></FONT><B><FONT STYLE="font-size: 10pt">&nbsp;<BR>
</FONT>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the<BR>
Securities Exchange Act of 1934<BR>
<BR>
</B><FONT STYLE="font-size: 10pt">Date of Report (Date of earliest event reported):<B> July 27, 2012<BR>
</B></FONT><B><FONT STYLE="font-size: 18pt">ALBANY MOLECULAR RESEARCH, INC.<BR>
</FONT></B><FONT STYLE="font-size: 10pt">(Exact Name of Registrant as Specified in Charter)<BR STYLE="mso-special-character: line-break">
<BR STYLE="mso-special-character: line-break">
</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; font-size: 10pt; font-weight: bold; text-align: center">Delaware</TD>
    <TD STYLE="width: 34%; font-size: 10pt; font-weight: bold; text-align: center">000-25323</TD>
    <TD STYLE="width: 33%; font-size: 10pt; font-weight: bold; text-align: center">14-1742717</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">File Number)</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">21 Corporate Circle, P.O. Box 15098, Albany, NY</TD>
    <TD STYLE="width: 50%; vertical-align: top; font-size: 10pt; font-weight: bold; text-align: center">12212</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(518) 512-2000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<I>see</I> General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01. Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 27, 2012 the
Board of Directors of Albany Molecular Research, Inc. (the &ldquo;Company&rdquo;) renewed its shareholder rights plan, as set forth
in the Shareholder Rights Agreement, dated July 27, 2012, between the Company and Computershare Shareowner Services LLC as Rights
Agent (the &ldquo;Rights Agreement&rdquo;). The following description of the terms of the Rights Agreement does not purport to
be complete and is qualified in its entirety by reference to the Rights Agreement which is attached hereto as an exhibit and is
incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms
of the Rights Agreement, the Board of Directors declared a dividend distribution of one Preferred Stock Purchase Right (a &ldquo;Right&rdquo;)
for each outstanding share of Common Stock of the Company (the &ldquo;Common Stock&rdquo;) to shareholders of record as of the
close of business on July 30, 2012 (the &ldquo;Record Date&rdquo;). In addition, one Right will automatically attach to each share
of Common Stock issued between the Record Date and the Distribution Date (as hereinafter defined). Each Right entitles the registered
holder thereof to purchase from the Company a unit consisting of one ten-thousandth of a share (a &ldquo;Unit&rdquo;) of Series
A Junior Participating Cumulative Preferred Stock, par value $0.01 per share, of the Company (the &ldquo;Preferred Stock&rdquo;)
at a cash exercise price of $18.25 per Unit (the &ldquo;Exercise Price&rdquo;), subject to adjustment, under certain conditions
specified in the Rights Agreement and summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Initially, the Rights
are not exercisable and are attached to and trade with all shares of Common Stock outstanding as of, and issued subsequent to,
the Record Date. The Rights will separate from the Common Stock and will become exercisable upon the earlier of (i) the close of
business on the tenth calendar day following the first public announcement that a person or group of affiliated or associated persons
(an &ldquo;Acquiring Person&rdquo;) has acquired beneficial ownership of 15% or more of the outstanding shares of Common Stock,
other than as a result of repurchases of stock by the Company or certain inadvertent actions by a shareholder (the date of said
announcement being referred to as the &ldquo;Stock Acquisition Date&rdquo;), or (ii) the close of business on the tenth business
day (or such later day as the Board of Directors may determine) following the commencement of a tender offer or exchange offer
that could result upon its consummation in a person or group becoming the beneficial owner of 15% or more of the outstanding shares
of Common Stock (the earlier of such dates being herein referred to as the &ldquo;Distribution Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, with respect to any person who beneficially owns (for purposes of the Rights Agreement) 15% or more of the outstanding
shares of Common Stock as of July 27, 2012 (such person being referred to in the Rights Agreement as a &ldquo;Grandfathered Person&rdquo;),
the Distribution Date will not occur unless such Grandfathered Person has acquired beneficial ownership of shares of Common Stock
representing an additional &frac12;% of the outstanding shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a
Stock Acquisition Date occurs, proper provision will be made so that each holder of a Right (other than an Acquiring Person or
its associates or affiliates, whose Rights shall become null and void) will thereafter have the right to receive upon exercise
that number of Units of Preferred Stock of the Company having a market value of two times the exercise price of the Right (such
right being referred to as the &ldquo;Subscription Right&rdquo;). In the event that, at any time following the Stock Acquisition
Date, (i) the Company consolidates with, or merges with and into, any other person, and the Company is not the continuing or surviving
corporation, (ii) any person consolidates with the Company, or merges with and into the Company and the Company is the continuing
or surviving corporation of such merger and, in connection with such merger, all or part of the shares of Common Stock are changed
into or exchanged for stock or other securities of any other person or cash or any other property, or (iii) 50% or more of the
Company&rsquo;s assets or earning power is sold, mortgaged or otherwise transferred, each holder of a Right (other than an Acquiring
Person or its associates or affiliates, whose Rights shall become null and void) will thereafter have the right to receive, upon
exercise, common stock of the acquiring company having a market value equal to two times the exercise price of the Right (such
right being referred to as the &ldquo;Merger Right&rdquo;). The holder of a Right will continue to have the Merger Right whether
or not such holder has exercised the Subscription Right. Rights that are or were beneficially owned by an Acquiring Person may
(under certain circumstances specified in the Rights Agreement) become null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Rights may be redeemed
in whole, but not in part, at a price of $0.01 per Right (payable in cash, Common Stock or other consideration deemed appropriate
by the Board of Directors) by the Board of Directors only until the earlier of (i) the time at which any person becomes an Acquiring
Person or (ii) the expiration date of the Rights Agreement. Immediately upon the action of the Board of Directors ordering redemption
of the Rights, the Rights will terminate and thereafter the only right of the holders of Rights will be to receive the redemption
price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Rights Agreement
may be amended by the Board of Directors in its sole discretion until the time at which any person becomes an Acquiring Person.
After such time the Board of Directors may, subject to certain limitations set forth in the Rights Agreement, amend the Rights
Agreement only to cure any ambiguity, defect or inconsistency, to shorten or lengthen any time period, or to make changes that
do not adversely affect the interests of Rights holders (excluding the interests of an Acquiring Person or its associates or affiliates).
In addition, the Board of Directors may at any time prior to the time at which any person becomes an Acquiring Person, amend the
Rights Agreement to lower the threshold at which a person becomes an Acquiring Person to not less than the greater of (i) the sum
of .001% and the largest percentage of the outstanding Common Stock then owned by any person and (ii) 10%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until a Right is exercised,
the holder will have no rights as a stockholder of the Company (beyond those as an existing stockholder), including the right to
vote or to receive dividends. While the distribution of the Rights will not be taxable to stockholders or to the Company, stockholders
may, depending upon the circumstances, recognize taxable income in the event that the Rights become exercisable for Units, other
securities of the Company, other consideration or for common stock of an acquiring company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the renewed
Rights Agreement contains a &ldquo;TIDE&rdquo; provision, which requires an independent committee of the Board of Directors to
review the Rights Agreement at least once every three years and to determine whether maintaining the Rights Agreement continues
to be in the best interest of the stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Rights are not exercisable until the
Distribution Date and will expire at the close of business on July 30, 2022 (the &ldquo;Expiration Date&rdquo;), unless previously
redeemed or exchanged by the Company as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with the entry into the Rights Agreement on July 27, 2012, the Company terminated on the same date </FONT>the Shareholder
Rights Agreement, dated September 18, 2002, between the Company and <FONT STYLE="font-family: Times New Roman, Times, Serif">Mellon
Investor Services LLC,</FONT> as Rights Agent (the &ldquo;Prior Rights Agreement&rdquo;). For a description of the terms and conditions
of the Prior Rights Agreement, please refer to the Company&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange
Commission on September 18, 2002, the text of which is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.02. Termination of a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please see the disclosure set forth under Item 1.01, which is
incorporated by reference into this Item 1.02.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3.03. <FONT STYLE="font-size: 10pt"> </FONT>Material
Modification to Rights of Security Holders. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please see the disclosure set forth under Item 1.01, which is
incorporated by reference into this Item 3.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01. Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 27, 2012, the Company issued a press release announcing
the renewal of the Rights Agreement.&nbsp; Please see the disclosure set forth under Item 1.01, which is incorporated by reference
into this Item 8.01.&nbsp;&nbsp; A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; text-align: justify">3.1</TD>
    <TD STYLE="width: 89%; text-align: justify">Amended and Restated Certificate of Designations, Preferences and Rights of a Series of Preferred Stock of Albany Molecular Research, Inc. classifying and designating the Series A Junior Participating Cumulative Preferred Stock., filed as an exhibit to the Company&rsquo;s Registration Statement on Form 8-A on July 27, 2012 and incorporated herein by reference.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.1</TD>
    <TD>Shareholder Rights Agreement, dated as of July 27, 2012, between Albany Molecular Research, Inc. and Computershare Shareowner Services LLC, as Rights Agent, filed as an exhibit to the Company&rsquo;s Registration Statement on Form 8-A on July 27, 2012 and incorporated herein by reference<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.2</TD>
    <TD>Amendment No. 2 to Shareholder Rights Agreement, dated as of July 27, 2012, between Albany Molecular Research, Inc. and Computershare Shareowner Services LLC, as Rights Agent (and successor to Mellon Investor services LLC), filed as an exhibit to the Company&rsquo;s Registration Statement on Form 8-A/A on July 27, 2012 and incorporated herein by reference.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>99.1</TD>
    <TD>Press Release issued by Albany Molecular Research, Inc. dated July 27, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1in">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>Date: July 31, 2012</TD>
    <TD COLSPAN="2">ALBANY MOLECULAR RESEARCH, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 59%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/ Mark T. Frost</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: Mark T. Frost</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Title: Senior Vice President, Administration,</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Chief Financial Officer and Treasurer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; font-weight: bold; text-decoration: none; border-bottom: Black 1pt solid">Exhibit No.</TD>
    <TD STYLE="width: 5%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 82%; font-weight: bold; text-decoration: none; border-bottom: Black 1pt solid">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 0.12in">3.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Amended and Restated Certificate of Designations, Preferences and Rights of a Series of Preferred Stock of Albany Molecular Research, Inc. classifying and designating the Series A Junior Participating Cumulative Preferred Stock., filed as an exhibit to the Company&rsquo;s Registration Statement on Form 8-A on July 27, 2012 and incorporated herein by reference.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 0.12in">4.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Shareholder Rights Agreement, dated as of July 27, 2012, between Albany Molecular Research, Inc. and Computershare Shareowner Services LLC, as Rights Agent, filed as an exhibit to the Company&rsquo;s Registration Statement on Form 8-A on July 27, 2012 and incorporated herein by reference<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.12in">4.2</TD>
    <TD>&nbsp;</TD>
    <TD>Amendment No. 2 to Shareholder Rights Agreement, dated as of July 27, 2012, between Albany Molecular Research, Inc. and Computershare Shareowner Services LLC, as Rights Agent (and successor to Mellon Investor services LLC), filed as an exhibit to the Company&rsquo;s Registration Statement on Form 8-A/A on July 27, 2012 and incorporated herein by reference.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.12in">99.1</TD>
    <TD>&nbsp;</TD>
    <TD>Press Release issued by Albany Molecular Research, Inc. dated July 27, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v319869_8k.htm", "description": "8-K", "secsgml_size_bytes": 29627}]
{"company-data": {"conformed-name": "ALBANY MOLECULAR RESEARCH INC", "cik": "0001065087", "assigned-sic": "8731", "irs-number": "141742717", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35622", "film-number": "12996966"}, "business-address": {"street1": "21 CORPORATE CIRCLE", "street2": "P O BOX 15098", "city": "ALBANY", "state": "NY", "zip": "12203-5154", "phone": "5184640279"}, "mail-address": {"street1": "21 CORPORATE CIRCLE", "street2": "P O BOX 15098", "city": "ALBANY", "state": "NY", "zip": "12203-5154"}}
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 27, 2012
ALBANY MOLECULAR RESEARCH, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
000-25323
14-1742717
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
21 Corporate Circle, P.O. Box 15098, Albany, NY
12212
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including
area code:
(518) 512-2000
(Former name or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
On July 27, 2012 the
Board of Directors of Albany Molecular Research, Inc. (the "Company") renewed its shareholder rights plan, as set forth
in the Shareholder Rights Agreement, dated July 27, 2012, between the Company and Computershare Shareowner Services LLC as Rights
Agent (the "Rights Agreement"). The following description of the terms of the Rights Agreement does not purport to
be complete and is qualified in its entirety by reference to the Rights Agreement which is attached hereto as an exhibit and is
incorporated herein by reference.
Pursuant to the terms
of the Rights Agreement, the Board of Directors declared a dividend distribution of one Preferred Stock Purchase Right (a "Right")
for each outstanding share of Common Stock of the Company (the "Common Stock") to shareholders of record as of the
close of business on July 30, 2012 (the "Record Date"). In addition, one Right will automatically attach to each share
of Common Stock issued between the Record Date and the Distribution Date (as hereinafter defined). Each Right entitles the registered
holder thereof to purchase from the Company a unit consisting of one ten-thousandth of a share (a "Unit") of Series
A Junior Participating Cumulative Preferred Stock, par value $0.01 per share, of the Company (the "Preferred Stock")
at a cash exercise price of $18.25 per Unit (the "Exercise Price"), subject to adjustment, under certain conditions
specified in the Rights Agreement and summarized below.
Initially, the Rights
are not exercisable and are attached to and trade with all shares of Common Stock outstanding as of, and issued subsequent to,
the Record Date. The Rights will separate from the Common Stock and will become exercisable upon the earlier of (i) the close of
business on the tenth calendar day following the first public announcement that a person or group of affiliated or associated persons
(an "Acquiring Person") has acquired beneficial ownership of 15% or more of the outstanding shares of Common Stock,
other than as a result of repurchases of stock by the Company or certain inadvertent actions by a shareholder (the date of said
announcement being referred to as the "Stock Acquisition Date"), or (ii) the close of business on the tenth business
day (or such later day as the Board of Directors may determine) following the commencement of a tender offer or exchange offer
that could result upon its consummation in a person or group becoming the beneficial owner of 15% or more of the outstanding shares
of Common Stock (the earlier of such dates being herein referred to as the "Distribution Date").
Notwithstanding the
foregoing, with respect to any person who beneficially owns (for purposes of the Rights Agreement) 15% or more of the outstanding
shares of Common Stock as of July 27, 2012 (such person being referred to in the Rights Agreement as a "Grandfathered Person"),
the Distribution Date will not occur unless such Grandfathered Person has acquired beneficial ownership of shares of Common Stock
representing an additional ½% of the outstanding shares of Common Stock.
In the event that a
Stock Acquisition Date occurs, proper provision will be made so that each holder of a Right (other than an Acquiring Person or
its associates or affiliates, whose Rights shall become null and void) will thereafter have the right to receive upon exercise
that number of Units of Preferred Stock of the Company having a market value of two times the exercise price of the Right (such
right being referred to as the "Subscription Right"). In the event that, at any time following the Stock Acquisition
Date, (i) the Company consolidates with, or merges with and into, any other person, and the Company is not the continuing or surviving
corporation, (ii) any person consolidates with the Company, or merges with and into the Company and the Company is the continuing
or surviving corporation of such merger and, in connection with such merger, all or part of the shares of Common Stock are changed
into or exchanged for stock or other securities of any other person or cash or any other property, or (iii) 50% or more of the
Company's assets or earning power is sold, mortgaged or otherwise transferred, each holder of a Right (other than an Acquiring
Person or its associates or affiliates, whose Rights shall become null and void) will thereafter have the right to receive, upon
exercise, common stock of the acquiring company having a market value equal to two times the exercise price of the Right (such
right being referred to as the "Merger Right"). The holder of a Right will continue to have the Merger Right whether
or not such holder has exercised the Subscription Right. Rights that are or were beneficially owned by an Acquiring Person may
(under certain circumstances specified in the Rights Agreement) become null and void.
The Rights may be redeemed
in whole, but not in part, at a price of $0.01 per Right (payable in cash, Common Stock or other consideration deemed appropriate
by the Board of Directors) by the Board of Directors only until the earlier of (i) the time at which any person becomes an Acquiring
Person or (ii) the expiration date of the Rights Agreement. Immediately upon the action of the Board of Directors ordering redemption
of the Rights, the Rights will terminate and thereafter the only right of the holders of Rights will be to receive the redemption
price.
The Rights Agreement
may be amended by the Board of Directors in its sole discretion until the time at which any person becomes an Acquiring Person.
After such time the Board of Directors may, subject to certain limitations set forth in the Rights Agreement, amend the Rights
Agreement only to cure any ambiguity, defect or inconsistency, to shorten or lengthen any time period, or to make changes that
do not adversely affect the interests of Rights holders (excluding the interests of an Acquiring Person or its associates or affiliates).
In addition, the Board of Directors may at any time prior to the time at which any person becomes an Acquiring Person, amend the
Rights Agreement to lower the threshold at which a person becomes an Acquiring Person to not less than the greater of (i) the sum
of .001% and the largest percentage of the outstanding Common Stock then owned by any person and (ii) 10%.
Until a Right is exercised,
the holder will have no rights as a stockholder of the Company (beyond those as an existing stockholder), including the right to
vote or to receive dividends. While the distribution of the Rights will not be taxable to stockholders or to the Company, stockholders
may, depending upon the circumstances, recognize taxable income in the event that the Rights become exercisable for Units, other
securities of the Company, other consideration or for common stock of an acquiring company.
Additionally, the renewed
Rights Agreement contains a "TIDE" provision, which requires an independent committee of the Board of Directors to
review the Rights Agreement at least once every three years and to determine whether maintaining the Rights Agreement continues
to be in the best interest of the stockholders.
The Rights are not exercisable until the
Distribution Date and will expire at the close of business on July 30, 2022 (the "Expiration Date"), unless previously
redeemed or exchanged by the Company as described below.
In
connection with the entry into the Rights Agreement on July 27, 2012, the Company terminated on the same date
the Shareholder
Rights Agreement, dated September 18, 2002, between the Company and
Mellon
Investor Services LLC,
as Rights Agent (the "Prior Rights Agreement"). For a description of the terms and conditions
of the Prior Rights Agreement, please refer to the Company's Current Report on Form 8-K filed with the Securities and Exchange
Commission on September 18, 2002, the text of which is incorporated by reference herein.
Item 1.02. Termination of a Material Definitive Agreement.
Please see the disclosure set forth under Item 1.01, which is
incorporated by reference into this Item 1.02.
Item 3.03.
Material
Modification to Rights of Security Holders.
Please see the disclosure set forth under Item 1.01, which is
incorporated by reference into this Item 3.03.
Item 8.01. Other Events.
On July 27, 2012, the Company issued a press release announcing
the renewal of the Rights Agreement.  Please see the disclosure set forth under Item 1.01, which is incorporated by reference
into this Item 8.01.   A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
Item 9.01.      	Financial Statements and Exhibits
(d)       	Exhibits.
3.1
Amended and Restated Certificate of Designations, Preferences and Rights of a Series of Preferred Stock of Albany Molecular Research, Inc. classifying and designating the Series A Junior Participating Cumulative Preferred Stock., filed as an exhibit to the Company's Registration Statement on Form 8-A on July 27, 2012 and incorporated herein by reference.
4.1
Shareholder Rights Agreement, dated as of July 27, 2012, between Albany Molecular Research, Inc. and Computershare Shareowner Services LLC, as Rights Agent, filed as an exhibit to the Company's Registration Statement on Form 8-A on July 27, 2012 and incorporated herein by reference
.
4.2
Amendment No. 2 to Shareholder Rights Agreement, dated as of July 27, 2012, between Albany Molecular Research, Inc. and Computershare Shareowner Services LLC, as Rights Agent (and successor to Mellon Investor services LLC), filed as an exhibit to the Company's Registration Statement on Form 8-A/A on July 27, 2012 and incorporated herein by reference.
99.1
Press Release issued by Albany Molecular Research, Inc. dated July 27, 2012.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 31, 2012
ALBANY MOLECULAR RESEARCH, INC.
By:
/s/ Mark T. Frost
Name: Mark T. Frost
Title: Senior Vice President, Administration,
Chief Financial Officer and Treasurer
EXHIBIT INDEX
Exhibit No.
Description
3.1
Amended and Restated Certificate of Designations, Preferences and Rights of a Series of Preferred Stock of Albany Molecular Research, Inc. classifying and designating the Series A Junior Participating Cumulative Preferred Stock., filed as an exhibit to the Company's Registration Statement on Form 8-A on July 27, 2012 and incorporated herein by reference.
4.1
Shareholder Rights Agreement, dated as of July 27, 2012, between Albany Molecular Research, Inc. and Computershare Shareowner Services LLC, as Rights Agent, filed as an exhibit to the Company's Registration Statement on Form 8-A on July 27, 2012 and incorporated herein by reference
.
4.2
Amendment No. 2 to Shareholder Rights Agreement, dated as of July 27, 2012, between Albany Molecular Research, Inc. and Computershare Shareowner Services LLC, as Rights Agent (and successor to Mellon Investor services LLC), filed as an exhibit to the Company's Registration Statement on Form 8-A/A on July 27, 2012 and incorporated herein by reference.
99.1
Press Release issued by Albany Molecular Research, Inc. dated July 27, 2012.